/forums/msspeaks/p/739 on gopher.createaforum.com

	Return Create A Forum - Home
	---------------------------------------------------------
	MS Speaks
	https://msspeaks.createaforum.com
	---------------------------------------------------------
	*****************************************************
	Return to: BETASERON (interferon beta-1b, Betaferon, Extavia)
	*****************************************************
	#Post#: 931--------------------------------------------------
	(Abst.) 10-yr. follow up of European multicenter trial of Betase
	ron in SPMS
	By: agate Date: September 13, 2015, 7:29 pm
	---------------------------------------------------------
	From PubMed, September 13, 2015:
	[quote]Mult Scler. 2015 Sep 11. pii: 1352458515594440.
	A 10-year follow-up of the European multicenter trial of
	interferon β-1b in secondary-progressive multiple sclerosis
	Kuhle J1, Hardmeier M2, Disanto G3, Gugleta K2, Ecsedi M2,
	Lienert C4, Amato MP5, Baum K6, Buttmann M7, Bayas A8, Brassat
	D9, Brochet B10, Confavreux C11, Edan G12, F�rkkil� M13,
	Fredrikson S14, Frontoni M15, D'Hooghe M16, Hutchinson M17, De
	Keyser J18, Kieseier BC19, K�mpfel T20, Rio J21, Polman C22,
	Roullet E23, Stolz C24, Vass K25, Wandinger KP26, Kappos L27;
	European Long-term Follow-up Study Group in Interferon β-1b
	in Secondary-progressive Multiple Sclerosis.
	Author information: [The authors are from the UK, Germany,
	France, Italy, Switzerland, Spain, Austria, and the Netherlands]
	OBJECTIVES:
	To explore long-term effects of treatment and prognostic
	relevance of variables assessed at baseline and during the
	European secondary progressive multiple sclerosis (SPMS) trial
	of interferon beta 1b (IFNB-1b).
	METHODS:
	We assessed 362 patients (60% female; median age 41 years;
	Expanded Disability Status Scale (EDSS): 5.5; 51% randomized to
	IFNB-1b) for their EDSS and treatment history after 10 years.
	Non-parametric analysis of covariance (ANCOVA) and multivariate
	linear regression models were applied.
	RESULTS:
	Median EDSS was 6.0 at the end of the randomized controlled
	trial (RCT), in the IFNB-1b and placebo groups, and 7.0 in
	long-term follow-up patients (those receiving IFNB-1b in the RCT
	were 6.5 and those receiving placebo in the RCT were 7.0; p =
	0.086). 24 patients (6.6%) were deceased. The EDSS at baseline
	and the EDSS change during the RCT were the most important
	predictors of the EDSS 10 years later (partial R2: 0.47). The
	ability to predict changes in EDSS 10 years after the RCT was
	limited (R2: 0.12). Magnetic resonance imaging (MRI) measures
	remained in the predictive models, but explained < 5% of the
	variability.
	CONCLUSIONS:
	The results from this analysis did not provide convincing
	evidence to support a favorable long-term outcome in those
	patients allocated IFNB-1b during the RCT, in our SPMS cohort.
	The progressive stage of the disease remains largely
	unpredictable by clinical and conventional MRI measures, so
	better prognostic markers are needed.[/quote]
	The abstract can be seen here
	http://www.ncbi.nlm.nih.gov/pubmed/26362898.
	*****************************************************